References
- Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223–2231
- Bowles K M, Warner B A, Baglin T P. Platelet mass has prognostic value in patients with myelodysplastic syndromes. Br J Haematol 2007; 138: 399–400
- Palmer S R, Tefferi A, Hanson C A, Steensma D P. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. Br J Haematol 2008; 140: 722–725
- Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett J M, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 2008; 113: 1351–1361
- Breccia M, Cannella L, Stefanizzi C, Latagliata R, Fama A, Santopietro M, et al. WPSS versus simplified myelodysplastic syndrome risk score: which is the best tool for prediction of survival in myelodysplastic patients?. Leuk Res 2008, [Epub ahead of print]